NCT06549465
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
Phase: Phase 2
Role: Lead Sponsor
Start: Aug 6, 2024
Completion: Apr 30, 2027